| 2019/06/28 08:02:19 | |
|---|---|
| Price | |
| 9.70 EUR | |
| Difference | 17.29% (1.43) |
General attributes
| ISIN | CH0106213793 |
| Symbol | POLN |
| Exchange | Berlin |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 5 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 9.70 EUR |
| High | 9.70 EUR |
| Low | 9.70 EUR |
| Close (prev. day) | 8.27 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 2 |
| Last size | 0 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: SPEXIS AG CHF0.02 |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2019/06/28 08:02:19 | |
|---|---|
| Price | |
| 9.70 EUR | |
| Difference | 17.29% (1.43) |
General attributes
| ISIN | CH0106213793 |
| Symbol | POLN |
| Exchange | Berlin |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 5 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 9.70 EUR |
| High | 9.70 EUR |
| Low | 9.70 EUR |
| Close (prev. day) | 8.27 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 2 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -37.98% | -64.31% | - |
| Perf (abs.) | -5.94 | -17.48 | - |
| Beta | 0.54 | -1.06 | 0.42 |
| Volatility | 125.04 | 93.42 | 91.49 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 8.66 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 10.00 EUR (3) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 16.03 EUR (6) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 20.68 EUR (7) |
| YTD High | date | 24.10 EUR (2019/04/16) |
| YTD Low | date | 8.27 EUR (2019/06/27) |
| 52 Weeks High | date | 30.26 EUR (2018/10/04) |
| 52 Weeks Low | date | 8.27 EUR (2019/06/27) |
All listings for SPEXIS AG CHF0.02
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| SIX Swiss Exchange | 2024/07/17 | 17:30 | 0.07 CHF | 0.01 | 15 |
| Frankfurt | 2019/06/28 | 15:43 | 10.18 EUR | 0.00 | 3 |
| Berlin | 2019/06/28 | 08:02 | 9.70 EUR | 0.00 | 2 |
Company Logo
Contact Details
| SPEXIS LTD. |
| - - |
| Hegenheimermattweg 125 - 4123 Allschwil |
| Telefon: +41-61-567-16-00 |
| Fax: +41-61-567-16-01 |
| E-mail: info@spexisbio.com |
PDF Downloads
| Company report: SPEXIS AG CHF0.02 | |
Company Profile
Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland. |
Members of Management Board
| Jeffrey D. Wager | Chairman of Managing Board |
| Jürgen Fröhlich | Member of Executive Committee |
Board of directors
| Dan Hartman | Member of the administrative board |
| Dennis Ausiello | Member of the administrative board |
| Kuno Sommer | Member of the administrative board |
| Robert Clarke | Member of the administrative board |
| Bernard Bollag | Member of the administrative board |